Menu
Washingtoner
  • Home
  • Boeing
  • Technology
  • Daryl Guberman
  • Aerospace
  • Health
  • ANSI-ANAB
  • Financial
  • Business
Washingtoner

Seagen Statement on Outcome of Daiichi Sankyo Arbitration
Washingtoner/10182820

Trending...
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
  • MainConcept Announces Multiview Encoding for Apple Immersive Video
  • Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.

"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."

More on Washingtoner
  • GDE Tree Services Expands Operations Across Logan, Ipswich and the Gold Coast
  • UK AltNet FullFibre Solves IPv4 Shortage With netElastic BNG And CGNAT Networking Software
  • Tacoma: Applicants Sought for the Equity in Contracting Advisory Committee
  • Tacoma: Hylebos Bridge Closed to Vehicular Traffic
  • Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

More on Washingtoner
  • Seven Games That Make You Think (and Smile) Earn 2026 Mensa Select® Honors
  • The Ramen Rater Unveils Top Ten Instant Noodles Of All Time – 2026 Edition
  • New Research Reveals Gen Z Trusts Independent Sources Over Influencers — Exposing What We are Talker Calls "The Independent Validation Gap"
  • City of Tacoma's Public Works Department Recognized by American Public Works Association
  • New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away

Contacts

For Media

David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
  • Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
  • Spring Into Your New Home at Heritage at South Brunswick
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • The Great Junk Hunt Returns to Its Roots in Puyallup
  • Mayor Anders Ibsen and Council Member Kristina Walker Urge Tacoma Residents to Participate in Sound Transit's Public Survey
  • HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
  • 5 Things to Check Before Calling for AC Repair in Philly
  • Go Dental Clinic Announces Upcoming Opening of New Branch in International City, Dubai
  • Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
  • City Seeks Community Members Interested in Preparing Statements 'For' and 'Against' Proposition 1, the 'Connect Tacoma: Safe Streets and Sidewalks' Ballot Measure
  • Contracting Resources Group and Aalis Management Consulting Launch ARG Joint Venture Under SBA Mentor-Protégé Program
  • Card makers turn to Pink and Main for tools to support their craft
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
  • EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
  • Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
_catLbl0 _catLbl1

Popular on Washingtoner

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 635
  • A Letter From the Tacoma City Council to the Sound Transit Board
  • Foiling Freaks Launches New Online Platform Dedicated to Foiling Board Sports
  • Tacoma: Lincoln Avenue Bridge to Close Saturday, April 18 for Asphalt Repairs
  • Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19
  • City Council to Discuss ‘Connect Tacoma’ Transportation Levy Replacement at April 14 Study Session
  • Spokane: Call for High School Artists: 2026 Riverfront Park Poster Contest
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
  • KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays

Similar on Washingtoner

  • As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Peernovation And Inception Stratos Launch Joint Venture To Build A Global Peer-powered Performance Platform
  • Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada
  • PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
  • Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute